{
    "clinical_study": {
        "@rank": "11685", 
        "arm_group": [
            {
                "arm_group_label": "SAD TD-6450", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single ascending dose (Part A)"
            }, 
            {
                "arm_group_label": "MAD TD-6450", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple ascending dose (Part B)"
            }, 
            {
                "arm_group_label": "Food effect of TD-6450", 
                "arm_group_type": "Active Comparator", 
                "description": "Food effect will be assessed in Part A (SAD) of this study."
            }
        ], 
        "brief_summary": {
            "textblock": "This study consists of two parts, Parts A and B.  Part A is a single ascending dose (SAD)\n      study in healthy subjects.  Part B is a multiple ascending dose (MAD) study in healthy\n      subjects."
        }, 
        "brief_title": "TD-6450 SAD and MAD in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a female of non-childbearing potential or male, who is healthy,\n             nonsmoking, and 18 to 60 years old, inclusive, at screening.  Females are considered\n             to be of non childbearing potential if they have had a hysterectomy or tubal ligation\n             (documentation required) or are postmenopausal (amenorrheic for at least 2 years)\n             with a follicle stimulating hormone (FSH) level >40 IU/L\n\n          -  Subject has a body mass index 18 to 30 kg/m2, inclusive, and weighs at least 50 kg.\n\n        Exclusion Criteria:\n\n          -  Subject has evidence or history of clinically significant allergic (except for\n             untreated, asymptomatic, seasonal allergies at time of dosing), hematological,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or\n             neurological disease.\n\n          -  Subject has an estimated creatinine clearance of <90 mL/min at Screening or Day -1,\n             calculated using the Cockcroft-Gault equation.\n\n          -  Subject has participated in another clinical trial of an investigational drug (or\n             medical device) within 60 days prior to Screening, or is currently participating in\n             another trial of an investigational drug (or medical device)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022306", 
            "org_study_id": "0094"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SAD TD-6450", 
                    "MAD TD-6450", 
                    "Food effect of TD-6450"
                ], 
                "intervention_name": "TD-6450", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "SAD TD-6450", 
                    "MAD TD-6450"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hepatitis C", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "last_name": "Monica Gonzalez", 
                "phone": "210-283-4541"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78209"
                }, 
                "name": "ICON Development Solutions"
            }, 
            "investigator": {
                "last_name": "Emanuel DeNoia, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects", 
        "overall_contact": {
            "email": "Rkohler@theravance.com", 
            "last_name": "Roger Kohler", 
            "phone": "650-808-6000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "28 days max"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetics", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "28 days max"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "28 days max"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "28 days max"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "28 days max"
            }, 
            {
                "description": "Measure difference between fasted and fed doses", 
                "measure": "Food effect on AUC value", 
                "safety_issue": "No", 
                "time_frame": "15 days max"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}